<DOC>
	<DOCNO>NCT03093181</DOCNO>
	<brief_summary>This study design evaluate cosmetic benefit provide twice daily application developmental moisturise cream niacinamide 8 week healthy female subject sensitive , oily , blemish-prone skin .</brief_summary>
	<brief_title>Investigation Cosmetic Benefit Provided Regular Application Moisturising Cream People With Blemish Prone Skin</brief_title>
	<detailed_description>This study broadly consist two phase : screen / washout phase ( 5-7 day ) follow treatment phase ( approximately 8 week ) . Subjects asked return study site 1 week , 4 week 8 week randomisation visit instrumental measurement clinical assessment .</detailed_description>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Demonstrates understand study procedure , restriction willingness participate evidenced voluntary write informed consent receive sign date copy inform consent form Good general mental health , opinion investigator medically qualify designee clinically significant relevant abnormality medical history upon physical examination Willingness actively participate study attend schedule visit Minimum 10 maximum 25 blemish ( papule pustule ) Visit 1 minimum 8 blemish ( papule pustule ) Visit 2 Fitzpatrick phototype IV Sebumeter score &gt; 66 Âµg / cm2 forehead Females childbearing potential , opinion investigator , practice reliable method contraception . Adequate contraception define abstinence , oral contraceptive , either combined progestogen alone OR injectable progestogen OR implant levonorgestrel OR estrogenic vaginal ring OR percutaneous contraceptive patch OR intrauterine device intrauterine system OR double barrier method ( condom occlusive cap [ diaphragm cervical vault cap ] plus spermicidal agent [ foam , gel , film , cream , suppository ] ) OR male partner sterilization prior female subject 's entry study , male sole partner subject Cleanses face least day Women know pregnant intend become pregnant duration study Women breastfeed Medical history use medicate acne treatment ( e.g . Benzoyl Peroxide , Clindamycin , isotretinoin ) within last 12 month Change contraception within last 3 month Active skin disease test area Medical history dysplastic nevus melanoma face Moles , cyst , tattoo , scar , irritated skin , hair , etc . test area could influence investigation Systemic therapy immunosuppressive drug ( e.g . corticosteroid ) and/or antihistamine within 7 day prior start study and/or throughout entire course study Systemic use antimicrobial within last month Systemic use overthecounter ( OTC ) analgesic antiinflammatory drug 24 hour prior dose first assessment visit One follow illness might require regular systemic medication : Insulindependent diabetes , cancer One follow illness medicate : Asthma , hypertension Medical history abnormal response sunlight History mental illness Medically diagnose acne vulgaris , acne conglobate , fulminans , secondary acne ( drug induce acne ) acne require systemic topical treatment No aesthetic , cosmetic dermatological treatment treatment area ( face ) within last month No intense sun exposure , UVtreatments tan salon visit within last 2 week Known suspected intolerance , allergy hypersensitivity study material ( closely relate compound ) state ingredient History allergy cosmetic product medicate acne treatment Participation another clinical study ( include cosmetic study ) receipt investigational drug within 30 day screen visit Previous participation study Recent history ( within last 5 year ) alcohol substance abuse An employee sponsor study site member immediate family</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>